Valeant seeks to add Solta’s products to its existing portfolio of skin-care treatments. Solta is a developer of medical devices for aesthetics including skin tightening treatment Fraxel and fat loss system Liposonix.
The deal is expected to close in Valeant’s fiscal first quarter, according to the report.
More Articles on Supply Chain:
MiMedx Group Supports CMS’s New Skin Substitute Reimbursement Methodology
Amerinet, Richard Wolf Enter Into Endoscopic Products Partnership
Janssen Therapeutics’ OLYSIO Inhibitor Receives FDA Approval for Hepatitis C Treatments
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
